Previous 10 | Next 10 |
Gilead Sciences (NASDAQ: GILD ) is an American biotechnology that researches, develops, and commercializes drugs. The company is best known for curing Hepatitis C, however, they have a portfolio of impressive assets. As we’ll see throughout this article, the company’s impressive...
Source: Barron's Gilead's ( GILD ) revenue has been uneven for several quarters. The company's top line has gone through fits and starts, and I am not sure if it will end any time soon. Q3 2019 revenue of $5.6 billion fell 1% Q/Q. This followed a high-single-digit percentage increase in ...
Amarin (NASDAQ: AMRN ) resumed with Neutral rating and $22 (5% upside) price target at JPMorgan. Shares down 2% premarket. More news on: Amarin Corporation plc, Glaukos Corporation, Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...
The past year has been great for stocks across the board, but that's made it awfully hard to find reliable dividend-paying stocks that offer satisfactory yields. The average dividend yield for stocks in the S&P 500 index has dwindled to just 1.8% at the moment, but there are stil...
Gilead Sciences (NASDAQ: GILD ) has submitted a marketing applicatio n to the FDA seeking approval of filgotinib for patients with moderate-to-severe rheumatoid arthritis. More news on: Gilead Sciences, Inc., Galapagos NV, Healthcare stocks news, Read more ...
As a contrarian investor, I am constantly looking for buying opportunities where the market is irrationally discounting stocks. Empirical research has shown that these contrarian investors on average achieve a high abnormal return. During this research I like to focus on free cash flows, as th...
Amgen (NASDAQ: AMGN ) resumed with Overweight rating and $280 (15% upside) price target at Morgan Stanley. More news on: Amgen Inc., Hill-Rom Holdings, Inc., Johnson & Johnson, Healthcare stocks news, Stocks on the move, , Read more ...
Arrowhead Pharmaceuticals (NASDAQ: ARWR ) initiated with Market Perform rating at Oppenheimer. More news on: Arrowhead Pharmaceuticals, Inc., Exact Sciences Corporation, Ionis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Galapagos NV (NASDAQ: GLPG ) announces the completion of enrollment of 33 subjects in a Phase 2a clinical trial, NOVESA , evaluating GLPG1690 in patients with diffuse cutaneous systemic sclerosis , an autoimmune disorder characterized by skin hardening and problems in many organs in the ...
November was a very strong month for the market, being up 3.40%. My portfolio underperformed the market by more than 1.50% due to bad Cisco Systems (CSCO) earnings and negative stock fluctuations for the cyclical company AMG ( AMVMF ). On the positive side, I cashed in half of my Galapagos ( G...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...